Evidence map›Paper›PMID 38363226›Full record

ArticleJournal of immunology (Baltimore, Md. : 1950)2024

Cytotoxic Programming of CD4+ T Cells Is Regulated by Opposing Actions of the Related Transcription Factors Eos and Aiolos.

Devin M Jones, Jasmine A Tuazon, Kaitlin A Read, Melissa R Leonard, Srijana Pokhrel, Bharath K Sreekumar, Robert T Warren, Jacob S Yount, Patrick L Collins, Kenneth J Oestreich

Open access · greenAbstract read
In one paragraph

Article in Journal of immunology (Baltimore, Md. : 1950), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.0field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 4 citations in OpenAlex.

  1. Local and circulating cytotoxic CD4medRxiv : the preprint server for health sciences · 2026
    Article
  2. Review
  3. Article
  4. Cytotoxic T Cells: Kill, Memorize, and Mask to Maintain Immune Homeostasis.International journal of molecular sciences · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 2 countries.

Devin M JonesDepartment of Microbial Infection and Immunity, The Ohio State University College of Medicine and Wexner Medical Center, Columbus, OH.
Jasmine A TuazonDepartment of Microbial Infection and Immunity, The Ohio State University College of Medicine and Wexner Medical Center, Columbus, OH.
Kaitlin A ReadDepartment of Microbial Infection and Immunity, The Ohio State University College of Medicine and Wexner Medical Center, Columbus, OH.
Melissa R LeonardDepartment of Microbial Infection and Immunity, The Ohio State University College of Medicine and Wexner Medical Center, Columbus, OH.ORCID 0000-0002-1680-3620
Srijana PokhrelDepartment of Microbial Infection and Immunity, The Ohio State University College of Medicine and Wexner Medical Center, Columbus, OH.ORCID 0009-0005-9629-4203
Bharath K SreekumarDepartment of Medicine; Gladstone Institute of Virology and Immunology, San Francisco, CA.
Robert T WarrenDepartment of Microbial Infection and Immunity, The Ohio State University College of Medicine and Wexner Medical Center, Columbus, OH.
Jacob S YountDepartment of Microbial Infection and Immunity, The Ohio State University College of Medicine and Wexner Medical Center, Columbus, OH.
Patrick L CollinsDepartment of Microbial Infection and Immunity, The Ohio State University College of Medicine and Wexner Medical Center, Columbus, OH.
Kenneth J OestreichDepartment of Microbial Infection and Immunity, The Ohio State University College of Medicine and Wexner Medical Center, Columbus, OH.ORCID 0000-0002-3004-072X
The Ohio State University Wexner Medical Center · USThe Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute · USGladstone Institutes · USOhio Department of Health · US

Funding

Translational Therapeutics Research Program (TT)P30CA016058 · NCI · OHIO STATE UNIVERSITY · PI Daniel G. Stover · 1985 to 2026
$132.3M
Mechanisms of innate resistance to virus infectionsR01AI130110 · NIAID · OHIO STATE UNIVERSITY · PI Jacob Yount · 2017 to 2026
$4.3M
Identifying novel regulatory pathways underlying T helper 1 cell immune responsesR01AI134972 · NIAID · VIRGINIA POLYTECHNIC INST AND ST UNIV · PI OESTREICH, KENNETH JOSEPH · 2018 to 2022
$1.9M
Interdisciplinary Program in Microbe-Host BiologyT32AI165391 · NIAID · OHIO STATE UNIVERSITY · PI RAJENDAR K DEORA, Daniel J Wozniak · 2022 to 2026
$1.5M
Gene regulatory architecture of CD56 bright natural killer cellsR21AI156411 · NIAID · OHIO STATE UNIVERSITY · PI COLLINS, PATRICK LEONARD · 2021 to 2022
$433k
Regulation of T helper cell differentiation by integrated STAT and Ikaros zinc finger transcription factor mechanismsR56AI127800 · NIAID · VIRGINIA POLYTECHNIC INST AND ST UNIV · PI OESTREICH, KENNETH JOSEPH · 2017 to 2017
$263k
The Ikaros zinc finger transcription factor Eos as a candidate regulator of TH2 differentiation and effector functionF30AI172189 · NIAID · OHIO STATE UNIVERSITY · PI TUAZON, JASMINE ASHLEY · 2024 to 2024
$37k
NCI NIH HHS P30 CA016058NIAID NIH HHS F30 AI172189NIAID NIH HHS R01 AI130110NIAID NIH HHS R01 AI134972NIAID NIH HHS R21 AI156411NIAID NIH HHS R56 AI127800NIAID NIH HHS T32 AI165391
6 · The paper itself

Abstract

In contrast to the "helper" activities of most CD4+ T effector subsets, CD4+ cytotoxic T lymphocytes (CD4-CTLs) perform functions normally associated with CD8+ T and NK cells. Specifically, CD4-CTLs secrete cytotoxic molecules and directly target and kill compromised cells in an MHC class II-restricted fashion. The functions of these cells have been described in diverse immunological contexts, including their ability to provide protection during antiviral and antitumor responses, as well as being implicated in autoimmunity. Despite their significance to human health, the complete mechanisms that govern their programming remain unclear. In this article, we identify the Ikaros zinc finger transcription factor Eos (Ikzf4) as a positive regulator of CD4-CTL differentiation during murine immune responses against influenza virus infection. We find that the frequency of Eos+ cells is elevated in lung CD4-CTL populations and that the cytotoxic gene program is compromised in Eos-deficient CD4+ T cells. Consequently, we observe a reduced frequency and number of lung-residing, influenza virus-responsive CD4-CTLs in the absence of Eos. Mechanistically, we determine that this is due, at least in part, to reduced expression of IL-2 and IL-15 cytokine receptor subunits on the surface of Eos-deficient CD4+ T cells, both of which support the CD4-CTL program. Finally, we find that Aiolos, a related Ikaros family member and known CD4-CTL antagonist, represses Eos expression by antagonizing STAT5-dependent activation of the Ikzf4 promoter. Collectively, our findings reveal a mechanism wherein Eos and Aiolos act in opposition to regulate cytotoxic programming of CD4+ T cells.

Indexed as

Antineoplastic AgentsCD4-Positive T-LymphocytesAnimalsCell DifferentiationCytokinesHumansMiceT-Lymphocytes, CytotoxicTranscription FactorsAntineoplastic AgentsCytokinesTranscription Factors

Identifiers

PMID38363226
PMCPMC10948294
OpenAlexW4391884804

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.